James Foster’s legendary half-century run at Charles River Laboratories is coming to an end. After more than 30 years as ...

Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.

Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the ...

Spiro Medical, which debuted last year, reeled in $67 million in series A funding it plans to use to develop its novel ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...

Impella, which J&J touts as the world’s smallest heart pump, has a range of devices used for various heart conditions. Lexeo ...

EpiBiologics launched in 2023 with a $50 million series A, having been founded to take forward the work of renowned antibody ...

Tessera Therapeutics is planning to lay off 90 employees, the Flagship-founded biotech has warned. | Tessera Therapeutics is ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital ...

It sounds like Lilly did just that. The U.S. pharma announced on Wednesday that it was paying $14 per share of Ventyx—more ...

In return for $10 million upfront, Foresee sold the global rights for its MMP-12 inhibitor programs to Primevera Therapeutics ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...